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Previous genome-wide association (GWA) studies typically focus on single-locus analysis, which may not have the power to detect the
majority of genuinely associated loci. Here, we applied pathway analysis using Affymetrix SNP genotype data from the Wellcome Trust
Case Control Consortium (WTCCC) and uncovered signiﬁcant association between Crohn Disease (CD) and the IL12/IL23 pathway,
harboring 20 genes (p ¼ 8 3 105). Interestingly, the pathway contains multiple genes (IL12B and JAK2) or homologs of genes
(STAT3 and CCR6) that were recently identiﬁed as genuine susceptibility genes only through meta-analysis of several GWA studies.
In addition, the pathway contains other susceptibility genes for CD, including IL18R1, JUN, IL12RB1, and TYK2, which do not reach
genome-wide signiﬁcance by single-marker association tests. The observed pathway-speciﬁc association signal was subsequently repli-
cated in three additional GWA studies of European and African American ancestry generated on the Illumina HumanHap550 platform.
Our study suggests that examination beyond individual SNP hits, by focusing on genetic networks and pathways, is important to un-
leashing the true power of GWA studies.Genome-wide association (GWA) studies have been
successfully employed to interrogate the genetic structure
of common and complex diseases.1 Through single-marker
association tests, several diseases, including Crohn disease
(CD [MIM 266600])2 and type 2 diabetes (T2D [MIM
125853]),3 have been studied by multiple groups and
have revealed tens of conﬁrmed susceptibility loci. Initial
insights from comparative analysis of different GWA
studies on the same disease suggest that the most signiﬁ-
cant SNPs in one study may not necessarily show up as
the most signiﬁcant SNPs in another study. Furthermore,
SNPs that are genuinely associated with disease may not
be identiﬁed by any GWA study because of the small effect
sizes of the SNPs and the lack of power of any individual
study. For example, of the 32 conﬁrmed susceptibility
loci for CD, 21 of them were not implicated in any given
GWA study but achieved signiﬁcance only after combining
three GWA studies and following up with replication.2
Similar observations have been made for other diseases,
in which genuine susceptibility loci do not rank as top in
any study but manifest moderate levels of signiﬁcance
across multiple studies.3,4 Given that most individual
GWA studies are probably underpowered to detect all butThe Amethe biggest effect sizes, the ‘‘most signiﬁcant SNPs’’
approach is less capable of separating the majority of truly
associated signals from background noise.
Rather than focusing on individual top SNPs from GWA
studies, we hypothesized that pathway-based approaches,
which jointly consider multiple variants in interacting or
related genes in the same pathway, might complement
the ‘‘most signiﬁcant SNPs’’ approach for interpreting data
from such studies.5 The pathway-based approach ranks
all genes by their statistical signiﬁcance and examines
whether a group of related genes have modest yet consis-
tent deviation fromwhat is expected by chance, simulating
a string of interconnected ‘‘needles in a haystack.’’ The
technical difﬁculty of the pathway-based approach lies
in the representation of each gene by multiple SNPs, the
handling of linkage disequilibrium (LD) between SNPs,
and the proper adjustment of different sizes of genes.6 We
have previously proposed an approach that appropriately
addresses these issues byusing aprocedure that is analogous
to gene set enrichment analysis.7
In brief, in our pathway-based association approach, we
associate each SNP to the overlapping gene or genes, or its
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Table 1. Description of the Four GWA Data Sets on Crohn Disease
GWA Data Set Number of Cases/Controls Ethnicity Array Platform
IL12/IL23 Pathway
Z Score
IL12/IL23 Pathway
p Value
WTCCC 1748/1480 European ancestry Affymetrix Mapping 500K 3.8 0.00008
Ped-IBD 647/4250 European ancestry Illumina HumanHap550 2.2 0.013
CDCC 1083/2507 European ancestry Illumina HumanHap550 3.3 0.0004
CHOP-CD-AA 40/527 African Americans Illumina HumanHap550 1.8 0.03a gene. For each gene, we assigned the highest statistic
value (chi-square value) among all SNPs mapped to the
gene as the statistic value of the gene. For all the N genes
that are represented by SNPs in the GWA study, we sorted
their statistic values from the largest to the smallest,
denoted by r(1),., r(N). For any given gene set S composed
of NH genes, we then calculated a weighted Kolmogorov-
Smirnov-like running sum statistic8 that reﬂects the
overrepresentation of genes within the set S at the top of
the entire ranked list of genes in the genome,
ESðSÞ ¼ max1%j%N
8<
:
X
Gj˛S,j%j
j rðjÞ j p
NR

X
Gj;S,j%j
1
N NH
9=
;
where NR ¼
P
Gj˛S, jrðjÞj
p and p (default value ¼ 1) is a
parameter that gives higher weight to genes with extreme
statistic values. To adjust for differences in gene size (hence
the different number of SNPs located within or nearby
each gene), as well as the linkage disequilibrium between
SNPs within the same gene, we conducted a two-step
correction procedure. In the ﬁrst step, we permuted the
disease labels of all samples, thereby ensuring the same
number of individuals in each phenotype group for case-
control studies. During each permutation (denoted by p),
we repeated the calculation of enrichment score as
described above as ES(S, p). In the second step, we calcu-
lated normalized enrichment score (NES) as a Z score,
deﬁned as (ES(S)  mean(ES(S, p)))/SD(ES(S, p)), so that
different gene sets are directly comparable to each other.
The p value can be calculated from the p permutations,
and a false discovery rate (FDR) procedure can be used to
control the fraction of expected false positive ﬁndings
below a certain threshold.9
In the present study, several adjustments were made in
our software implementation: (1)We used the latest RefSeq
gene annotated in UCSC genome browser10 (as of
September 2008) to deﬁne the genomic region for each
gene in the NCBI 36 genome assembly; the ‘‘genomic
span’’ for each gene corresponds to the entire RefSeq tran-
script region, as well as the 20 kb up/downstream of the
transcript. (2) We have used the Cochran-Armitage trend
test for the single-marker association test and used the chi-
square values as the test statistic for each SNP. (3) We used
an updated version of the Gene Ontology11 level 4 annota-
tion data sets, as well as updated version of the BioCarta
database and the KEGG database12 (as of September 2008)
for our pathway collection.400 The American Journal of Human Genetics 84, 399–405, March 1This pathway-based association approach requires the
use of individual-level genotype data for all SNPs in a given
GWA study rather than summary statistics only. To test our
pathway-based association approach on CD, we accessed
the raw genotype data on the CD case cohort and on the
1958 birth control cohort from the Wellcome Trust Case
Control Consortium (WTCCC), which were generated
using the Affymetrix GeneChip Mapping 500K array sets
with ~500,000 SNP markers.13 Per WTCCC recommenda-
tions as speciﬁed in the ‘‘exclusion-list-05-02-2007.txt’’
ﬁle, 24 control subjects as well as 257 CD cases were
not used in study. Therefore, 1748 CD patients and
1480 control subjects of European ancestry were used in
our study. We have downloaded the genotype calls gener-
ated by the Chiamo calling algorithm; per recommenda-
tions by the Chiamo software and the WTCCC study, we
only considered those genotype calls with conﬁdence
score >0.9 and treated the rest of the calls as missing geno-
types. Per WTCCC guideline as speciﬁed in the ‘‘exclusion-
list-snps-26_04_2007.txt’’ ﬁle, we have removed 30,956
SNPs from the AffymetrixMapping 500K array from associ-
ation analysis. The genomic control inﬂation factor14 on
single-marker association analysis for this data set is 1.1.
After additional quality-control procedures (removal of
markers with call rate <95%, minor allele frequency <1%,
or markers that are >100 kb away from any gene), a total
of ~272,000 SNPs representing 16,958 RefSeq genes were
used in our pathway-based association analysis.We applied
25,000 permutation cycles and tested the association on
534 pathways and gene sets with default parameters in
our software.5 The top-ranked pathway is the IL12 pathway
with 20 genes (Z ¼ 3.8, permutation p ¼ 0.00008, Bonfer-
roni-adjusted p ¼ 0.043, FDR ¼ 0.045, Table 1), whereas
several additional pathways with FDR <0.25 are listed in
Table S1 available online.
Examination of the 20 genes within the IL12 pathway
demonstrates that a subset of these genes, including Janus
kinase 2 (JAK2 [MIM 147796]), tyrosine kinase 2 (TYK2
[MIM 176941]), interleukin 12 receptor 1 (IL12RB1 [MIM
601604]), and interleukin 12 precursor (IL12B [MIM
601642]), also belong to a gene network that is typically
referred to as the ‘‘IL23 pathway.’’15 Given that the term
‘‘IL23 pathway’’ has not been annotated in the public
pathway collection, we have elected to use the term
‘‘IL12/IL23 pathway’’ in the discussion below to be consis-
tent with existing CD literature. Multiple plausible hits
related to CD biology are contained within the IL12/IL233, 2009
pathway. Three genes, including the interleukin12 receptor
2 (IL12RB2 [MIM601642]) on1p31.3, IL12Bon5q33.3, and
IL12RB1 on 19p13.11, rank as the three most signiﬁcant
genes in thepathwaybasedon themost signiﬁcant SNP rep-
resenting each gene. In cells, IL12RB1 and IL12RB2 form
a high-afﬁnity receptor for IL12, which consists of the
IL12A and IL12B subunits, whereas IL12RB2 and inter-
leukin 23 receptor (IL23R [MIM 607562]) form a receptor
for IL23 signaling.16 As the ﬁrstCD susceptibility gene iden-
tiﬁed by a GWA study,17 IL23R associates constitutively
with JAK2 and the transcription activator STAT3 (MIM
102582).16 Interestingly, neither JAK2 nor IL12B have
been implicated by any single published GWA study on
CD, but they have both been recently identiﬁed as CD
susceptibility genes in a meta-analysis of GWA data.2 To
test their effects on pathway association, we eliminated
JAK2 and IL12B from the pathway, and we still obtained
signiﬁcant association of the pathway with CD (Z ¼ 3.3,
permutation p ¼ 83 105), indicating that the association
results were not dependent on these known susceptibility
genes. Furthermore, another two genes in the IL12/IL23
pathway, namely STAT4 (MIM 600558) and CCR5 (MIM
601373), are both in the same protein family of conﬁrmed
CD susceptibility genes (STAT3 [MIM 102582] and CCR6
[MIM 601835]).2 Therefore, variants conferring modest
disease risk may not reveal themselves in multiple under-
powered GWA studies, but can be readily identiﬁed by
pathway-based approach in a single study.
To replicate the pathway association results, we analyzed
several additional GWA data sets generated on the Illumina
HumanHap550 arrays with ~550,000 SNP markers, which
represent mostly different markers as the Affymetrix arrays
used byWTCCC.We ﬁrst examined a previously published
GWA study on pediatric-onset inﬂammatory bowel disease
(IBD) (the Ped-IBD cohort, Table 1), including 647 CD cases
and 4250 control subjects of European ancestry.18 In brief,
affected individuals with pediatric-onset IBD were ascer-
tained through the Children’s Hospital of Philadelphia,
Children’s Hospital of Wisconsin and Medical College of
Wisconsin, and Cincinnati Children’s Hospital Medical
Center. However, because the IBD cases include subjects
affected by either CD or with ulcerative colitis (UC), we
only keep the 647 CD cases in our association analysis.
The control group included 4250 children recruited at the
Children’s Hospital of Philadelphia (CHOP) of European
ancestry. The Research Ethics Board of the respective hospi-
tals and other participating centers approved the study, and
written informed consent was obtained from all subjects.
The genomic control inﬂation factor14 is calculated as 1.1,
similar to the level in the WTCCC data set. With similar
quality-control measures as those used on the WTCCC
data set, a total of ~373,000 SNPs representing 17,410 genes
remained in the analysis. Notably, the IL12/IL23 pathway
showed statistically signiﬁcant association with CD (Z ¼
2.2, permutation p ¼ 0.013), indicating that the pathway
association results replicated with a different technical
platform and marker sets.The AmeFurther replication was demonstrated in our expanded
and ongoing GWA study on CD, including 1083 indepen-
dent pediatric-onset CD cases and 2507 control subjects
of European ancestry (the CDCC cohort, Table 1). The
samples from the CDCC data set were collected from
multiple centers from four geographically discrete coun-
tries, including Italy (13.3%), Scotland (15.5%), Canada
(21.9%), and United States (49.3%). All patients were diag-
nosed prior to their nineteenth birthday and fulﬁlled stan-
dard CD diagnostic criteria. Phenotypic characterization
was based on a modiﬁcation of the Montreal classiﬁcation
such that the deﬁnitions of L1 and L3 were both extended
to include disease within the small bowel proximal to the
terminal ileum and distal to the ligament of Treitz. The
control group was recruited by CHOP clinicians and
nursing staff within theCHOPHealthCareNetwork,which
includes primary care clinics and outpatient practices. The
control subjects did not have IBD or evidence of chronic
disease on the basis of the self-reported intake question-
naire or clinician-based assessment. The research ethics
board of the respective hospitals and other participating
centers approved the study, and written informed consent
was obtained from all subjects. We used multidimensional
scaling (MDS) by PLINK19 on genotyping data to ensure
the matching of ethnicity groups and to include only
subjects of European ancestry. Appropriate care has been
taken to ensure that none of the cases or controls overlaps
with the Ped-IBD data set described above. The genomic
control inﬂation factor14 is calculatedas 1.08.After applying
thoroughquality-controlmeasures, a total of ~368,000SNPs
representing 17,404 genes remained in the analysis. The
IL12/IL23pathway still showed statistically signiﬁcant asso-
ciation with CD (Z ¼ 3.3, permutation p ¼ 0.0004), further
corroborating the results from the Ped-IBD cohort.
To demonstrate the diverse applicability of the pathway-
based approach, we next investigated whether the associa-
tion results could be replicated in a different ethnic group.
Accordingly,we examined a fourthGWAstudydata set con-
taining 40 African American CD cases and 527 matched-
control subjects (the CHOP-CD-AA cohort, Table 1). All
CD patients were identiﬁedwithin the CHOP through elec-
tronic examination of medical records in the EPIC clinical
databases, corresponding to ~20,000 Philadelphia children
recently genotyped on the Illumina HumanHap550 plat-
form. The controls were randomly selected from the afore-
mentioned population sample and were genetically
matched to the CD cases. The Research Ethics Board of
CHOP approved the study, and written informed consent
was obtained from all subjects. The genomic control inﬂa-
tion factor14 is calculated as 1.00. Despite the small sample
size, the IL12/IL23 pathway is still signiﬁcantly associated
withCD(Z¼1.8, permutationp¼0.03), further conﬁrming
the potential involvement of the pathway in the pathogen-
esis of CD in subjects of African ancestry.
Comparison of the test statistic values for genes in the
IL12/IL23 pathway between the four GWA studies demon-
strates that the relative ranking of genes was quite differentrican Journal of Human Genetics 84, 399–405, March 13, 2009 401
Figure 1. The Chi-Square Values and Negative Logarithm of p Values of the Most Significant SNPs for Each of the 20 Genes
in the IL12/IL23 Pathway in Four GWA Data Sets
The CCR5 gene is not represented by SNPs in the Illumina arrays. The relative ranking of the genes are different between the four GWA
studies; however, as a group, they collectively show moderately high association signals in each of the GWA studies.(Figure 1 and Table S2). Furthermore, we also examined
SNPs tagging these genes in the recent Barrett et al. CD
meta-analysis results2 (Table S3) and found that several
previously unreported IL12/IL23 pathway genes indeed
score well in the meta-analysis, albeit not reaching
genome-wide signiﬁcance (for example, p ¼ 1.2 3 104
for rs1035127 representing IL18R1, p ¼ 3.9 3 104 for
rs6661505 representing JUN, p ¼ 7.8 3 104 for rs374326
representing IL12RB1, p ¼ 5.7 3 103 for rs12720356 rep-
resenting TYK2). Despite the drastically different associa-
tion results on the level of individual SNPs across studies,
the pathway was consistently picked up as being associated
with CD in all four GWA studies, demonstrating the power
and effectiveness of pathway association approach in iden-
tifying disease-susceptibility mechanisms.
Although our study represents a successful example of
a pathway-based approach in relation with GWA studies,
several caveats need to be addressed. First, the success of
such an analysis depends on the accurate annotation of402 The American Journal of Human Genetics 84, 399–405, March 1each pathway as well as the comprehensiveness of the
pathway collection, with respect to the disease of interest.
For example, previous GWA studies have implicated
autophagy-related molecules in the pathogenesis of CD,
on the basis of association signals at the immunity-related
GTPase M protein (IRGM [MIM 608212]) locus20 and the
autophagy-related 16-like 1 gene (ATG16L1 [MIM
610767]) locus.21 Given that this pathway is not well char-
acterized (in fact, IRGM is not even annotated as a RefSeq
gene), we constructed a hypothetical pathway containing
all genes with ‘‘autophagy’’ in their RefSeq description as
well as IRGM (15 genes in the Affymetrix array, 17 genes
in the Illumina array). Weak evidence of association was
identiﬁed for the autophagy pathway, with p value of
0.002, 0.05, 0.24, and 0.29 for the four data sets in Table 1,
respectively. Similarly, the nucleotide-binding oligomeriza-
tion domain 2 (NOD2 [MIM 605956]) gene is a well-known
CD susceptibility gene,22,23 but it was not annotated in any
pathwayused in our study, so our approach cannot account3, 2009
for the effect of this gene on CD susceptibility. These two
examples demonstrate that deﬁciencies in pathway collec-
tion could lead to loss of power to detect genuine disease-
susceptibility mechanisms.
Another potential limitation of the pathway association
approach is that themethod cannot readily distinguish the
scenario in which each of the susceptibility genes confers
moderate risk to disease versus the scenario in whichmajor
effect genes in a pathway play dominant roles. For some
diseases, such as type 1 diabetes, major effect loci (HLA
loci) exist that may easily mask the contribution from
other loci with small effect sizes. To demonstrate this, we
have analyzed the WTCCC data set on type 1 diabetes
and found that essentially any pathway containing the
HLA genes generates highly signiﬁcant p values, even if
HLA genes are the only genes with evidence of association
to the disease in the pathway. Thus, appropriate adjust-
ments may be required to reﬂect the contribution of minor
effect loci in certain disease areas.
We also caution that the assignment of test statistic for
a SNP to its closest gene may not always be correct, given
that the culprit gene could be farther away from the risk
SNP than the closest gene. For example, in our data, the
SNP rs7546245 was assigned to represent its closest gene
IL12RB2 (22 kb away); however, the SNP is only 25 kb
away from IL23R, a well-known CD susceptibility gene. In
fact, rs7546245 is in moderate linkage disequilibrium (r2 ¼
0.48) with rs11805303 (the most signiﬁcant SNP for IL23R
reported by WTCCC13), suggesting that it may indeed tag
a variant within IL23R. Similar examples in GWA studies
have been previously reported: the most signiﬁcant SNP
for lactase persistence is not located within the biochemi-
cally veriﬁed gene LCT (MIM 603202) but within introns
of a nearby gene;24,25 similarly, the most signiﬁcant SNP
for human height near the Indian hedgehog homolog
(IHH [MIM 600726]) locus is located within a nearby gene
rather than IHH, which is known to be the true causal
gene on the basis of monogenic syndrome caused bymuta-
tion in the gene as well as knockout mouse phenotype.26
Altogether, these issues need to be considered when per-
forming and interpreting pathway-based association tests
on GWA studies.
Our study has signiﬁcant implications with respect to CD
biology andmay broaden the options for therapy. Treatment
with a monoclonal antibody against IL12 in patients with
active CD has been shown to induce clinical responses and
remissions.27,28 Molecular evidence implicating the role for
key members of the pathway, such as STAT429 and MAP
kinase,30,31 is also accumulating. Although GWA studies
have been proven useful to identify commondisease-suscep-
tibility variants in speciﬁc human populations, biologically
importantgenesdonotnecessarilycontaincommonvariants
with high odds ratio. Therefore, by identifying the ensemble
ofbiologically relevantgenes,pathway-basedapproaches can
help formulate hypotheses. As such, other members in the
IL12/IL23 pathway may also serve as functional candidates
for detailed molecular studies or as promising therapeuticThe Ametargets. Furthermore, some additional pathways may not
reach stringent criteria for signiﬁcance but are still worth
examining. For example, the list in Table S1 contains two
T cell receptor signaling pathways from different pathway
sources, conﬁrming the involvement of cellular immunity
in CD pathogenesis.32,33 In fact, PTPN2 (MIM 176887) and
PTPN22 (MIM 600716), two Tcell protein tyrosine phospha-
tases, have now been ﬁrmly established as CD susceptibility
genes.2 In addition, ATP-binding cassette (ABC) transporters
rank as the fourth most signiﬁcant pathway, and ABCB1
(MIM171050) in thepathwayhasbeenpreviously associated
with inﬂammatory bowel diseases.34,35
Our study also has signiﬁcant implications regarding efﬁ-
cient analysis of GWA data. The successful identiﬁcation
and replication of a CD susceptibility pathway demon-
strates the power and applicability of the pathway-based
approach in the analysis of GWA data. By switching the
focus from single SNPs to gene pathways and gene
networks, we can potentially aggregate information from
multiple susceptibility loci and eliminate the notoriously
inherent noise in GWA data. In conclusion, in order to
take the full advantage of the information carried in high-
density GWA data sets, we need to take steps that go
beyond the conventional approaches of assessing only
top SNP hits.
Supplemental Data
Supplemental Data include three tables and can be foundwith this
article online at http://www.ajhg.org/.
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